Literature DB >> 15652293

Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.

H C Flick-Smith1, E L Waters, N J Walker, J Miller, A J Stagg, M Green, E D Williamson.   

Abstract

In order to evaluate the immunogenicity and protective efficacy of anthrax vaccine candidates a suitable small animal model is required. The inbred A/J strain of mouse has been selected as a potential model, and its immune response to immunisation with recombinant protective antigen (rPA) vaccine characterised, by assessment of rPA specific antibody production, and protection against injected challenge, with the unencapsulated STI strain of Bacillus anthracis. Studies were conducted to determine the time required post immunisation to develop a protective immune response, to define the minimum protective dose of vaccine required and to assess the long-term immune response to immunisation. From the results of these studies it was possible to establish that the A/J mouse is a consistent and robust small animal model for rPA vaccine testing. A comparison of the immune response to rPA vaccine immunisation in the Turner Outbred (TO) mouse strain was also conducted. Both inbred and outbred mouse strains displayed a predominantly Th2 biased immune response and showed a comparable antibody response to rPA immunisation. An assessment of protection in the TO mouse against aerosol challenge with the fully virulent strain of B. anthracis, Ames, was also made.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15652293     DOI: 10.1016/j.micpath.2004.10.007

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  18 in total

1.  Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice.

Authors:  Michael S Petrik; Margaret C Wong; Rena C Tabata; Robert F Garry; Christopher A Shaw
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.

Authors:  C K Cote; L Kaatz; J Reinhardt; J Bozue; S A Tobery; A D Bassett; P Sanz; S C Darnell; F Alem; A D O'Brien; S L Welkos
Journal:  J Med Microbiol       Date:  2012-07-05       Impact factor: 2.472

3.  Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Authors:  Crystal L Loving; Taruna Khurana; Manuel Osorio; Gloria M Lee; Vanessa K Kelly; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

4.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

5.  A novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system.

Authors:  Yu-Tsueng Liu; Shwu-Bin Lin; Cheng-Po Huang; Chun-Ming Huang
Journal:  Protein Expr Purif       Date:  2007-09-14       Impact factor: 1.650

6.  Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.

Authors:  Nareen Abboud; Arturo Casadevall
Journal:  Clin Vaccine Immunol       Date:  2008-05-14

7.  Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus).

Authors:  Mark S Lever; Anthony J Stagg; Michelle Nelson; Peter Pearce; Daniel J Stevens; Elizabeth A M Scott; Andrew J H Simpson; Mark J Fulop
Journal:  Int J Exp Pathol       Date:  2008-06       Impact factor: 1.925

8.  Serodiagnosis of human cutaneous anthrax in India using an indirect anti-lethal factor IgG enzyme-linked immunosorbent assay.

Authors:  N Ghosh; I Tomar; H Lukka; A K Goel
Journal:  Clin Vaccine Immunol       Date:  2012-12-26

9.  Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.

Authors:  Yves P Gauthier; Jean-Nicolas Tournier; Jean-Charles Paucod; Jean-Philippe Corre; Michèle Mock; Pierre L Goossens; Dominique R Vidal
Journal:  Infect Immun       Date:  2008-12-29       Impact factor: 3.441

10.  Immunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis Ames.

Authors:  James M Vergis; Christopher K Cote; Joel Bozue; Farhang Alem; Christy L Ventura; Susan L Welkos; Alison D O'Brien
Journal:  Clin Vaccine Immunol       Date:  2012-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.